Coronavirus: England’s contact-tracing app gets green light for trial

Public tests are set to start on Thursday, but concerns remain about how accurately distance is measured.

Share Button

Efficient valves for electron spins

Researchers at the University of Basel in collaboration with colleagues from Pisa have developed a new concept that uses the electron spin to switch an electrical current. In addition to fundamental research, such spin valves are also the key elements in spintronics — a type of electronics that exploits the spin instead of the charge of electrons. The results were published in the scientific journal Communications Physics.

At some point, spintronics might become a buzzword that is as much a part of our vocabulary as electronics. The idea behind it is to use the angular momentum (spin) of an electron instead of the electrical charge. Researchers around the world have been pursuing this goal for many years. Spintronics promises numerous applications in information storage and processing, and could improve the energy efficiency of electronic devices. An important prerequisite is the efficient control and detection of electron spins.

A team of physicists around Professor Christian Schönenberger and Dr. Andreas Baumgartner from the Swiss Nanoscience Institute and the Department of Physics at the University of Basel has now developed a new technique for spintronics in semiconductor devices. Researchers from the Instituto Nanoscienze-CNR in Pisa were also involved.

Nanomagnets are the key

For this purpose, the scientists form two small semiconductor islands (quantum dots) behind each other on a nanowire and generate magnetic fields in the quantum dots using nanomagnets. Using an external field, they are able to control these magnets individually and thus can determine whether a quantum dot allows electrons to pass with a spin directed upward (up) or downward (down). When two quantum dots are connected in series, a current only flows if both are set to “up” or both to “down.” Ideally, no current flows if they are oriented in opposite directions.

Arunav Bordoloi, first author of the publication and PhD student in the Schönenberger team, found that this method produced a spin polarization close to the theoretical maximum. “With this technique, we can choose whether a single electron in a given spin state is allowed to enter or leave a quantum system — with an efficiency far greater than in conventional spin valves,” he says.

“In recent years, researchers around the world found it a hard nut to crack to fabricate spin valves useful for nano- and quantum-electronic devices,” says Dr. Andreas Baumgartner, who is supervising the project. “We have now succeeded in producing one.”

Exploring new phenomena

The physicists were also able to show that the magnetic fields are localized to specific locations on the nanowire. “This technique should therefore allow us to study the spin properties of new phenomena typically too sensitive to magnetic fields, such as novel states at the ends of special superconductors,” comments Dr. Baumgartner.

This new approach to spintronics should now enable direct measurements of spin correlations and spin entanglement and shed new light on many old and new physical phenomena. In the future, the concept could even prove useful in the quest to use electron spins as the smallest information unit (quantum bit) in a quantum computer.

Story Source:

Materials provided by University of Basel. Note: Content may be edited for style and length.

Share Button

Internal differences: A new method for seeing into cells

Invading cells’ private space — prying into their internal functions, decisions and communications — could be a powerful tool that may help researchers develop new immunotherapy treatment for cancer. As reported today in Cell, a research group at the Weizmann Institute of Science has developed a technology that enables them to see inside tens of thousands of individual cells at once in greater details than ever before. The group, headed by Prof. Ido Amit of the Institute’s Immunology Department, applied this method to define the immune cells that infiltrate tumors, identifying a new subset of innate immune cells that “collaborate” with cancer. Blocking these inhibitory immune cells in mice greatly enhanced the anti-tumor immune response, killing the cancer.

Amit and his group had previously made significant inroads into seeing into cells when they developed single cell RNA-sequencing — a means of sequencing all of the RNA in thousands of individual cells at once. The new technique, called INs-seq (intracellular staining and sequencing) — developed in Amit’s lab in a project led by research students Yonatan Katzenelenbogen, Fadi Sheban, Adam Yalin and Dr. Assaf Weiner — enables scientists to measure, in addition to the RNA, numerous proteins, processes and biochemical pathways occurring inside each of the cells. To do this, they had to develop new methods of getting inside the cell membranes without harming its genetic content. This wealth of “inside information” can help them draw much finer distinctions between different cell subtypes and activities than is possible with existing methods, most of which are able to measure surface proteins only.

In fact, Amit compares those existing methods of cell characterization with buying watermelons: They all appear identical from the outside, even though they can taste completely different when you open them up. Distinguishing between subtypes of cells that seem identical from the outside, such as inhibitory- versus effector-immune cells, may be crucial to when it comes to fighting off cancer.

Although the principal groups of immune cells had been identified many decades ago, there are hundreds of subtypes with many different functions, which haven’t been classified. “Specific immune subtypes, for example, may play a role in promoting cancer or enabling it to evade the immune system, provoke tissue destruction by overreacting to a virus or act mistakenly in autoimmune syndromes, attacking our own body. Until now, there was no sufficiently sensitive means of telling these apart from other subtypes that appear identical from the outside,” says Sheban.

In order to sort through these different immune functions inside tumors, the Weizmann scientists used their technology to address an issue that researchers had been trying to resolve for decades: Why does the immune system fail to recognize and kill cancer cells, and why does immunotherapy for most tumor types often fail? In searching for an answer, they asked whether cancers might hijack and manipulate particular immune cells to “defend” the cancer cells from the rest of the immune system. “The suspicion that some kind of immune cell might be actively ‘collaborating’ with cancer is not as strange as it seems,” explains Yalin. “Immune responses are often meant to be short-lived, so the immune system has its own mechanisms for shutting them down. Cancers could take advantage of such mechanisms, enhancing the production of the ‘shut-down’ immune cells, which, in turn, could prevent such immune cells as T lymphocytes that would normally kill them from taking action.”

Indeed, the team succeeded in identifying T-cell-blocking immune cells, which belonged to a general group known as myeloid cells — a broad group of innate immune cells that mostly originate in the bone marrow. Although this particular subset of suppressive myeloid cells was new, it was distinguished by a prominent signaling receptor that Amit and his group had seen before, called TREM2. This receptor is critical for the activity of the cells that block the actions of tumor-killing T cells; and normally cells bearing this receptor are crucial for preventing excess tissue damage after injury or calming an inflammatory immune response. But Amit had also come across a version of this receptor in other immune cells involved in Alzheimer’s disease, metabolic syndrome and other immune-related pathologies.

The group’s next step is to develop an immunotherapy treatment using specific antibodies that target this receptor and could prevent these immune-suppressive cells from supporting the tumor. “Because this receptor is only expressed when there is some type of pathology,” says Weiner, “targeting it will not damage healthy cells in the body.”

Preliminary evidence for the TREM2 therapeutics was demonstrated by the scientists in mouse models of cancer with genetically ablated TREM2 receptors. In those mice, tumor-killing T cells “came back to life” and attacked the cancer cells; and the tumors shrank significantly. If treatment based on this finding is, in the future, proven effective for human use, it might be administered on its own or in combination with other forms of immunotherapy.

Yeda Research and Development, the technology transfer arm of the Weizmann Institute of Science, is currently working with Amit to develop this immunotherapy antibody for clinical use and there has already been a great deal of interest in INs-seq technology. “Clarifying the mechanisms of autoimmune and neurodegenerative diseases, and answering the question of why the immune system often fails in its fight against cancer or why most patient do not respond to existing immunotherapy — all of these may come down to specific actions of subsets of immune cells. We believe INs-seq may help researchers identify those particular cells and develop new therapies to treat them,” says Katzenelenbogen.

Share Button

Upcycling plastic waste toward sustainable energy storage

What if you could solve two of Earth’s biggest problems in one stroke? UC Riverside engineers have developed a way to recycle plastic waste, such as soda or water bottles, into a nanomaterial useful for energy storage.

Mihri and Cengiz Ozkan and their students have been working for years on creating improved energy storage materials from sustainable sources, such as glass bottles, beach sand, Silly Putty, and portabella mushrooms. Their latest success could reduce plastic pollution and hasten the transition to 100% clean energy.

“Thirty percent of the global car fleet is expected to be electric by 2040, and high cost of raw battery materials is a challenge,” said Mihri Ozkan, a professor of electrical engineering in UCR’s Marlan and Rosemary Bourns College of Engineering. “Using waste from landfill and upcycling plastic bottles could lower the total cost of batteries while making the battery production sustainable on top of eliminating plastic pollution worldwide.”

In an open-access article published in Energy Storage, the researchers describe a sustainable, straightforward process for upcycling polyethylene terephthalate plastic waste, or PET, found in soda bottles and many other consumer products, into a porous carbon nanostructure.

They first dissolved pieces of PET plastic bottles in a solvent. Then, using a process called electrospinning, they fabricated microscopic fibers from the polymer and carbonized the plastic threads in a furnace. After mixing with a binder and a conductive agent, the material was then dried and assembled into an electric double-layer supercapacitor within a coin-cell type format.

When tested in the supercapacitor, the material contained the characteristics of both a double-layer capacitor formed by the arrangement of separated ionic and electronic charges, as well as redox reaction pseudo-capacitance that occurs when the ions are electrochemically absorbed onto surfaces of materials.

Though they don’t store as much energy as lithium-ion batteries, these supercapacitors can charge much faster, making batteries based on plastic waste a good option for many applications.

By “doping” the electrospun fibers prior to carbonization with various chemicals and minerals such as boron, nitrogen, and phosphorus, the team plans to tune the final material to have improved electrical properties.

“At UCR, we have taken the first steps toward recycling plastic waste into a rechargeable energy storage device,” said doctoral student and first author Arash Mirjalili. “We believe that this work has environmental and economic advantages and our approach can present opportunities for future research and development.”

The authors believe the process is scalable and marketable, and that it represents major progress toward keeping waste PET out of landfills and the oceans.

“The upcycling of PET plastic waste for energy storage applications could be considered the holy grail for green manufacturing of electrode materials from sustainable waste sources,” said mechanical engineering professor Cengiz Ozkan. “This demonstration of a new class of electrodes in the making of supercapacitors will be followed by a new generation of Li-ion batteries in the future, so stay tuned.”

Story Source:

Materials provided by University of California – Riverside. Original written by Holly Ober. Note: Content may be edited for style and length.

Share Button

Cosmetic surgeon struck off after botched ops

Patients awarded thousands in compensation have not been paid as he did not have insurance.

Share Button

Training and Performance

In many jobs your working hours are performance hours. You’re expected to do the work that creates value. If you’re a programmer, you get paid to program. If you’re a lawyer, you get paid to help people solve legal problems.

But in some jobs, performance is just a small slice of paid time on the job.

Consider a professional basketball player, for instance. The performance time is during competitive games with other teams. Game time performance is what creates the value for the franchise, the fans, the sponsors, and the other stakeholders.

But for the athletes, most of the time on the job isn’t performance time. During those other hours, they’re training, practicing, being coached, preparing, recovering, etc. Of course this is still important work so they can be prepared to perform well during televised games.

What if you currently do work that’s mostly performance but you approach it like a professional athlete? What would that look like?

Where is your job closest to the performance of a pro athlete? Which activities really count in terms of delivering value and earning your pay?

Most likely your hours on the job aren’t all equal in terms of delivering value. Some activities may be more critical than others, especially when it comes to career advancement or business success.

Do you know what those critical activities are?

Once you know the critical activities, where’s the training portion of your day? Where’s the ongoing investment in further honing your skills, so you can get better and better at the performance side? Are you investing in enough training… or barely any?

I could frame blogging as a performance activity since my articles are public facing and provide value to people. I could then imagine many hours of private journaling, reading, experimenting, and exploring to be training and practice.

Alternatively, I could frame blogging as a practice or training activity. And I could imagine a larger project like writing a book, creating a course, or delivering a workshop as a performance activity.

The reality is that I use both frames and often flip between them. Sometimes I see blogging as a way to beta-test ideas. Other times I see it as a core activity for delivering value to people. The framing is flexible. But what isn’t so flexible is that some form of training and practice is necessary. Whichever frame I use, training and practice must be an essential part of it.

Alternatively, suppose you view your work as 100% performance time. There is no practice and training while you’re on the clock. How does that framing sit with you? Does it suggest that if you want to improve, you have to devote some of your personal unpaid time to training and skill-building? I think that’s exactly what it suggests.

While you do get some performance gains from training, it’s best not to confuse the two. Training gives you more coverage of different skills than performance alone ever will. You may practice situations in training that you’ll rarely experience on the performance side, yet it’s critical to have those skills when they’re needed. With training you can also break down the fundamental skills and work on them more thoroughly than you can on the performance side.

Imagine that 90% (or more) of your work time is just practice and training, and 10% (or less) is real performance time. If you use this lens, which activities would you put on each side?

What are your most critical skills that provide the most value? What would happen if you devoted the other 90% of your work time to honing and training up those skills to an even higher level?

Suppose you create and publish videos as your main work product. All the value you provide is in your published videos. Now suppose you spent 90% of your work time just training and practicing your video skills – but not publishing any of that work. Do you think that would impact what you’re able to deliver with the other 10%?

The 90-10 ratios are arbitrary by the way. You could use 80-20, 50-50, or anything else that appeals to you. What ratios make you reconsider your approach to work? I like the extreme of 90-10 thinking because it gets me closer to the mindset of a pro athlete who has to invest an extraordinary amount of training and practice time for a small amount of performance time. In reality their ratio is likely to be even more extreme than 90-10, especially if you consider Olympic athletes who may train years for a single performance (which in some cases may be measured in seconds).

Play around with this frame. You don’t have to use it exclusively, but it can be an interesting way to think about work and productivity. What if you approached your work like a pro athlete whereby the vast majority of your work time was treated as training and practice for a small but important slice of critical performance time? Could this (or something close to it) be a better model than seeing your work at 100% performance time?

Share Button

Health24.com | Antiviral drugs tied to heart issue in Covid-19 patients

  • Two common antiretroviral drugs given to Covid-19 patients can cause bradycardia, a serious slowing of the heart
  • These drugs had been considered a promising treatment for Covid -19
  • Going forward, the experimental antiviral drug remdesivir appears to be a much more effective alternative 

Older, critically ill Covid-19 patients who are given a combination of two common antiretroviral drugs can experience a drastic slowing of their heart rate, French researchers report.

In their study of 41 patients treated with lopinavir and ritonavir twice daily for 10 days, 22% developed a slow heart rate condition called bradycardia. When the drugs were stopped or doses lowered, the patients’ heart rates returned to normal, according to the team from Amiens University Hospital, in France.

“There are extensive investigations underway to find therapies that are effective at treating patients infected with Covid-19,” said Dr Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, who had no part in the study.

Potential for bradycardia

The lopinavir-ritonavir combo had been considered a promising treatment for Covid-19 based on very small reports, randomised clinical trials and off-label use, Fonarow said.

But earlier studies have suggested that this combination may also lead to heart block, a problem with electrical signals in the heart. “Determining how these drugs lead to the bradycardia will require further study,” Fonarow said.

Doctors prescribing these drugs should be aware of the potential for bradycardia and carefully monitor patients, he added.

“Moreover, preliminary clinical trial results suggest this therapy is not effective in Covid-19, so use in this setting will likely be very limited going forward,” Fonarow said.

Lopinavir and ritonavir have also been used to treat other viruses, including SARS (severe acute respiratory syndrome), MERS (Middle East respiratory syndrome) and HIV. The researchers noted that bradycardia has also been seen among HIV patients treated with the drugs.

Normally, adults’ hearts beat between 60 and 100 times a minute. In bradycardia, the rate falls below 60 beats per minute, causing decreased blood flow that can lead to fainting, chest pain, low blood pressure and heart failure.

Combo not well tolerated

Patients in the French study who developed the problem were older than ones who did not, averaging 62 to 80 years of age, the researchers reported.

Dr Marc Siegel, a professor of medicine at NYU Langone Medical Center in New York City who reviewed the findings, noted that the two-drug combo had not helped hospitalised Covid-19 patients in other recent trials.

Siegel said the treatment should not be used with Covid-19 because it’s not effective in either critically ill patients or in the early stages of the disease.

“The remaining hope for this combination of drugs was early in the disease, but the significant amount of bradycardia in these critically ill patients raises the question that this combo is not well tolerated in many patients,” he said.

Going forward, Siegel said, the experimental antiviral drug remdesivir appears to be effective and is already being used to fight Covid-19.

The new study, by Dr Christophe Beyls and colleagues, was published early in 9 July  in the journal Circulation: Arrhythmia and Electrophysiology.

Image credit:

Share Button

Health24.com | Scientists find source of Covid-19 clots

  • Many Covid-19 patients present with blood clots that can be deadly
  • These blood clots are linked to the endothelial cells that line the inside of blood vessels 
  • Researchers are trying to find strategies to safeguard the endothelial layer and prevent blood clots from forming

Covid-19 is linked to potentially fatal blood clots. Researchers now believe they’ve found out how they occur, which potentially could lead to better treatment.

“While many forms of illness can generate blood clots, the endothelial cells that line the inside of blood vessels play a surprisingly large role in Covid-19 clotting,” said researcher Dr Alfred Lee, an associate professor of medicine at Yale Cancer Center.

“Endothelial damage is a central component in the entire spectrum of Covid-19 disease. Our study is the first to demonstrate that this process of endothelial damage is present in a wide range of Covid-19 patients, particularly as people become critically ill,” Lee said in a Yale news release.

For the study, Lee and his team examined the blood of 68 patients with Covid-19. Of these patients, 48 were critically ill in an ICU. The other 20 were hospitalised but not in the ICU.

Therapeutic strategies

The researchers found that some markers of endothelial cell and blood platelet activation were nearly twice as high in the ICU patients compared to those not in the ICU.

One marker, called thrombomodulin, was linked with survival among all patients. Measuring thrombomodulin might help doctors better treat patients, the researchers say.

“If we have a marker to identify which patients are most likely to progress towards critical illness and possibly death, that would be hugely helpful, as these patients might benefit from closer monitoring and possibly earlier intervention,” Lee said.

Study co-author Dr Hyung Chun is trying to develop a test based on thrombomodulin, which is elevated in other life-threatening diseases as well.

“The other goal we’re pursuing in parallel is to find therapeutic strategies that could safeguard the endothelial layer and may prevent the blood clots from forming,” said Chun, an associate professor of medicine and pathology at Yale School of Medicine. “Are there approved drugs we could potentially repurpose for this context?”

One possible candidate is the drug dipyridamole, used to prevent stroke.

The report was published late in June in the journal The Lancet Haematology.

Image credit:

Share Button

Coronavirus: Exposure rate ‘similar’ in London and Stockholm

Antibody tests suggest similar exposure to the virus in the two capitals, despite different strategies.

Share Button

Coronavirus: Severe mental health problems rise amid pandemic

An NHS Confederation report predicts a 20% increase in demand for services in the coming months.

Share Button